Three in four people with asthma are at risk of ‘fatal attacks’

More than three quarters of asthma sufferers could be susceptible to having a fatal asthma attack because they incorrectly assume their asthma is under control, according to new research.

A survey conducted by Allergy UK and funded by Novartis Pharmaceuticals UK, discovered this finding and many other things to raise alarm bells about the serious lung condition which afflicts around 5.4 million in Britain. Moreover, asthma costs the NHS an estimated £1 billion per year for the treatment and care for asthma patients.

464 participants with asthma were involved in the survey, and 78% who stated their asthma as being mild or moderate go through up to four blue reliever inhalers each month. “In reality they shouldn’t even need to use one per month if their disease is well controlled,” the charity says.

This finding backs up what Medical Specialists® Pharmacy said back in May, how a good proportion of asthmatics and not realising the massive importance of the brown preventer inhalers in building up a long-term resistance to triggers for asthma attacks.

Allergy UK adds that of the respondents who wrongly believe their condition is adequately under control, 16% have had six or more days off from work or school in the past 12 months because of their asthma.

The charity also discovered that up to 60% of asthma attacks are caused by allergens such as animal dander, house dust mites, pollen, mould and foods. Only 37% of those surveyed had been tested for allergies and the charity says that a drive to provide allergy tests could reduce the number of asthma attacks as patients would be more aware of their specific triggers.

Lindsey McManus, the Deputy CEO of Allergy UK, said: “Asthma is a killer, with three people dying of it every day in the UK. These shocking survey results reflect what we hear time and time again from the people that call our helpline. People ‘put up with’ their asthma symptoms and continue to use medication that isn’t treating the inflammation, rather than seeking help to get their asthma under control. They just don’t realise they are putting themselves in danger and could soon find themselves in A&E.”

More than one in five sufferers (22%) involved in the survey had not had an asthma review for at least a year it was discovered.

Ms McManus added: “Our biggest piece of advice is to talk to your doctor or asthma nurse. They will conduct a thorough asthma review and may refer you to a specialist who may conduct an allergy assessment and review your asthma management. This is the only way to ensure that the asthma crisis doesn’t worsen.”

Dr Monica Nordstrom, Respiratory Physician at Ashford and St. Peter’s Hospitals NHS Foundation Trust commented: “Doctors, nurses and patients themselves often fail to recognise whether asthma is moderate or severe, leading to life-threatening attacks that could have been avoided with appropriate diagnosis and management.

“There are three warning signs for patients to look out for; if you use more than one reliever inhaler a month; if you’ve been prescribed one or more courses of oral corticosteroids in the past 12 months or if you are consistently missing work or school because of your asthma – these can all be signs that your asthma may be more severe than you think and you should seek more help from your doctor or specialist nurse.”

Asthma drug salbutamol amazingly helped teenager’s paralysis

Could the popular blue reliever inhaler Ventolin Evohaler also be used to relieve…paralysis?!
An 18-year-old suffering with congenital myasthenia, an inherited neuromuscular disorder, took salbutamol and after a week the teen stunned doctors by being able to walk unaided after being wheelchair-bound for seven years.

Jimmy Webster, from Cardiff, had been suffering to such an extent that he had required an oxygen mask to breathe on occasions.

On taking salbutamol, Mr Webster commented: “Within three days I could stand and within a week I could walk.” Next on the agenda for Jimmy is a camping trip. He said: “I wouldn’t have contemplated this last year.”

Salbutamol is a fast-acting medicine used in the treatment of asthma, bronchospasm and is also sometimes used for delaying the delivery in women going through a premature labour. The drug is a beta-2-agonist, and works by relaxing the muscles within air passages of the lungs. This means the airways are kept open and it is much easier to breathe.

However, Jimmy’s experience could pave the way for salbutamol being a main treatment option for more of the estimated 12,000 Brit’s with myasthenia.

Myasthenia can either be inherited, or caused by an autoimmune disorder. This means that the immune system – usually working to protect the body from infections – mistakenly attacks its own tissues.

Those with the autoimmune type of myasthenia have a fault in the transmission of nerve messages from the nerves to the muscles. This results in the muscles not being stimulated correctly and therefore do not tighten (contract) sufficiently, becoming easily tired and weak.

Muscle weakness is a particularly common symptom of the disease, but there are a range of symptoms – which may appear suddenly. Weakness in the eye muscles is often the first symptom, with one or both of the eyelids drooping, and there may also be blurred or double vision.

For some, the muscles around the mouth are affected first, resulting in problems with swallowing (dysphagia), chewing and even talking. Impaired speech and a nasal-sounding voice then usually follow.

Like in Jimmy’s case, some people with the condition can have breathing difficulties, especially during exercise or lying flat, and in some extreme scenarios, myasthenia can cause total paralysis.
Previous studies that shown a similar drug – ephedrine – contained in cold and flu remedies, could occasionally be effective for treating myasthenia. For example, there was another teenage patient who ended up being able to go out jogging and do sit-ups after previously having to rely on crutches to walk.

Therefore, Professor David Beeson at the Weatherall Institute, of Molecular Medicine, Oxford University, wanted to find other drugs that could be just as effective, if not better. Salbutamol was one of the medicines analysed.

Salbutamol may be used in conjunction with other drugs or standalone. Professor Beeson commented: “It is not yet licensed for use in the condition, but clinicians are happy to prescribe it.”
He advised Jimmy to try salbutamol together with pyridostigmine, a treatment he had been on since the age of four.

“I expected I’d get stronger, but had no idea I’d be able to walk again,” says Jimmy. “I still use my wheelchair out and about, but at home I walk around – just getting dressed, washing and cooking, it’s amazing to be able to normal things.”

Professor Beeson is delighted with Jimmy’s progress, adding: “It is incredibly rewarding to see results like this. Over the last couple of years we have seen patients rise from their wheelchairs within months, but Jimmy’s quite exceptional.”